Organon : Q1 2025 Earnings Presentation Opens a new window

Published: 2025-05-01 09:23:52 ET OGN

Published on 05/01/2025 at 09:23

First Quarter 2025 Earnings

This presentation contains "non-GAAP financial measures," which are financial measures that either exclude or include amounts that are correspondingly not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles ("GAAP"). Specifically, the company makes use of the non-GAAP financial measures Adjusted EBITDA, Adjusted EBITDA margin, Adjusted gross margin, Adjusted gross profit, Adjusted net income, and Adjusted diluted EPS, which are not recognized terms under GAAP and are presented only as a supplement to the company's GAAP financial statements. This presentation also provides certain measures that exclude the impact of foreign exchange. We calculate foreign exchange by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. The company believes that these non-GAAP financial measures help to enhance an understanding of the company's financial performance. However, the presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the company's results as reported under GAAP. Because not all companies use identical calculations, the presentations of these non-GAAP measures may not be comparable to other similarly titled measures of other companies. Please refer to Slides 17-19 of this presentation for additional information, including relevant definitions and reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures.

In addition, the company's full-year 2025 guidance measures (other than revenue) are provided on a non-GAAP basis because the company is unable to reasonably predict certain items contained in the GAAP measures. Such items include, but are not limited to, acquisition-related expenses, restructuring and related expenses, stock-based compensation, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts and other items not reflective of the company's ongoing operations.

The company's management uses the non-GAAP financial measures described above to evaluate the company's performance and to guide operational and financial decision making. Further, the company's management believes that these non-GAAP financial measures, which exclude certain items, help to enhance its ability to meaningfully communicate its underlying business performance, financial condition and results of operations.

See Slides 17-19 of this presentation for a reconciliation of non-GAAP measures. 3

Revenue of $1.5 billion, down 4% ex-FX, consistent with phasing of LOE of Atozet

Diluted EPS of $0.33; Adj. Diluted EPS of $1.02

Adj. EBITDA of $484 million, representing 32.0% Adjusted EBITDA margin

Full year 2025 financial guidance affirmed

See Slides 17-19 of this presentation for a reconciliation of non-GAAP measures.

LOE = Loss of Exclusivity 4

Other (1), 2%

~75% of

FY sales generated ex-US (2)

Totals may not foot due to rounding, and percentages are computed using unrounded amounts.

"Other" includes manufacturing sales to third parties.

Above chart based on Q1 2025 revenue

5

Disclaimer

Organon & Co. published this content on May 01, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 01, 2025 at 13:22 UTC.